Stay updated on Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4, replacing the previous v3.5.3, indicating a deployment update to the ClinicalTrials.gov page.
    Difference
    0.1%
    Check dated 2026-05-15T15:19:09.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page revision label was updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-24T06:18:30.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:40:31.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Study status updated to Active, not recruiting and enrollment set to 38, with revised study dates. Contact information for the study team has been updated.
    Difference
    1%
    Check dated 2026-03-19T05:29:06.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    - Revision updated: v3.4.3 added; v3.4.2 removed.
    Difference
    0.1%
    Check dated 2026-03-12T02:27:35.000Z thumbnail image
  9. Check
    103 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the government-funding notice and prior Revision: v3.4.1 from the page.
    Difference
    0.4%
    Check dated 2026-02-11T11:55:29.000Z thumbnail image

Stay in the know with updates to Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.